<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00617981</url>
  </required_header>
  <id_info>
    <org_study_id>104-06-301</org_study_id>
    <nct_id>NCT00617981</nct_id>
  </id_info>
  <brief_title>Phase 3 Study of ThermoDox With Radiofrequency Ablation (RFA) in Treatment of Hepatocellular Carcinoma (HCC)</brief_title>
  <official_title>A Phase III, Randomized, Double-Blinded, Dummy-Controlled Study of the Efficacy and Safety of ThermoDox® (Thermally Sensitive Liposomal Doxorubicin) in Combination With Radiofrequency Ablation (RFA) Compared to RFA-Alone in the Treatment of Non-Resectable Hepatocellular Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celsion</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celsion</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether ThermoDox, a thermally sensitive liposomal
      doxorubicin, is effective in the treatment of non-resectable hepatocellular carcinoma when
      used in conjunction with radiofrequency ablation (RFA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This will be a Phase III, randomized, double-blinded, dummy-controlled, efficacy, and safety
      study of ThermoDox plus RFA versus RFA plus dummy infusion.

      The 50 mg/m2 ThermoDox or dummy infusion will be administered IV over 30 minutes. As part of
      blinded pre-medication ThermoDox treated subjects will receive 20 mg of dexamethasone orally
      48 hours prior to the drug infusion for infusion reaction prophylaxis. Subjects on the
      control arm will receive a matching dummy pre-medication pill orally at 48 hours prior to
      infusion of the study treatment. Thirty minutes prior to receiving the ThermoDox infusion,
      subjects will receive a blinded dose of 20 mg of IV dexamethasone, 50 mg IV diphenhydramine
      and either 50 mg of IV ranitidine or 20 mg of IV famotidine. Subjects on the control arm will
      receive a masked dummy pre-medication pill orally at 48 hours prior to infusion of the study
      medication, and a dummy infusion 30 minutes prior to dummy infusion of D5W (250 cc of 5%
      Dextrose solution). RFA will be initiated approximately at a minimum of 15 minutes after the
      initiation of study drug infusion and should be completed no later than 3 hours after study
      drug infusion initiation. The total length of the RFA procedure is proportional to the size
      of the tumor(s) involved and is anticipated to range from 12 to 60 minutes for each lesion
      with an estimated overall procedure time of less than 3 hours.

      Subjects with incomplete ablations will be re-treated to complete the ablation according to
      the treatment assigned at randomization. The completion of an ablation in this manner will
      restart the timeline of the study-related visits/procedures. This repeated ablation procedure
      cannot occur earlier than 21 days post-ablation but no later than 14 days after the first
      post-ablation CT scan assessment. These subjects will start over at screening (see Table 1).
      If a complete ablation is not achieved after these two study treatments, the subject will be
      considered a treatment failure and the patient will be discontinued and followed for survival
      only.

      Subjects who recur with local and/or distant intrahepatic HCC after a complete initial
      ablation will have met the primary endpoint of progression-free survival. However, if these
      subjects have lesions that are amenable to RFA the standard of care is to consider them for
      repeat RFA. Therefore, these subjects may receive treatment to which they were randomized if
      they continue to meet the inclusion and exclusion criteria of the protocol. Subjects who
      develop any extrahepatic lesion will have met the primary endpoint and will be discontinued
      from study treatment but will still be followed for overall survival.

      Dynamic Contrast CT imaging will be used to assess the effectiveness of the ablation therapy.
      The blind will be maintained at the level of CT scan reads. All protocol-specified CT images
      will be centrally read and assessed by the endpoint committee in a blinded fashion.
      Posttreatment CT scans will be obtained at months 1, 3, 5, 7, 9 and 12 and every three months
      thereafter until withdrawal. Adverse event assessments and laboratory examinations will occur
      at each visit. All subjects will be monitored throughout the investigational period.

      Patients that meet inclusion/exclusion criteria may be at risk for contrast-induced
      nephropathy (CIN) when undergoing the required CT with contrast procedures. The investigators
      must be mindful of the risk factors (e.g. diabetes, borderline renal function) associated
      with CIN and employ strategies to reduce the risk of CIN. In subjects with diabetes or
      borderline renal function (creatinine greater than 1.5 mg/dL) special precautions (e.g.
      hydration, contrast dose reduction, follow up creatinine determination) should be employed.
      An accepted procedure is adequate intravenous volume expansion with isotonic saline (1.0 -
      1.5 mL/kg per hour) for 3-12 hours before the procedure and continued for 6-24 hours.

      All randomized subjects will be followed for safety and overall survival.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 2008</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause</measure>
    <time_frame>3 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall Survival as Measured by Time From Randomization to Death or the End of the Study.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Definite Worsening as Per Patient-Reported Outcomes</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Local Recurrence.</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety</measure>
    <time_frame>3 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">701</enrollment>
  <condition>Hepatocellular Carcinoma</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Sham Comparator</arm_group_type>
    <description>Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ThermoDox</intervention_name>
    <description>Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5% Dextrose Solution</intervention_name>
    <description>Single 30 minute intravenous infusion</description>
    <arm_group_label>2</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Diagnosed hepatocellular carcinoma (HCC)

          -  No more than 4 HCC lesions with at least one ≥ 3.0 cm and none &gt; 7.0 cm in maximum
             diameter, based on diagnosis at screening.

          -  If a subject has a large lesion (5.0 - 7.0 cm), any other lesions must be less than
             5.0 cm.

          -  Anticipated ablation volume will be no larger than either removal of 3 hepatic
             segments or removal of more than 30% of total liver volume (as per maximum surgical
             limit).

          -  If additional lesions are discovered during the laparoscopic or open treatment
             procedure, that were undetectable by CT at screening, the size and location of the
             lesion(s) will be recorded in the CRF and the lesions will be treated at the
             discretion of the physician and guided by the local standard of care. The subject will
             remain on study if all lesions are treated. If any lesions cannot be completely
             ablated within two treatment attempts the subject will be considered a treatment
             failure.

          -  Study subjects being considered for re-treatment after disease progression may have
             more than 4 lesions.

          -  Male or female 18 years of age or older.

          -  Are willing to sign an informed consent form, indicating that they are aware of the
             investigational nature of this study that is in keeping with the policies of the
             institution.

          -  Be an appropriate candidate for receiving RFA as a medically indicated treatment as
             evaluated by the following factors:

               -  Number of lesions

               -  Size of lesions

               -  Overall health of liver

               -  Not a candidate for surgical resection

          -  Have an echocardiogram revealing a Left Ventricular Ejection Fraction (LVEF) ≥ 50%.
             Measurements with a multiple gated acquisition (MUGA) scan are allowed if an
             echocardiogram cannot be performed. The same method of measurement should be used to
             evaluate ejection fraction (EF) of the subject for the duration of the study.

          -  Willing to return to the study site for their study visits.

          -  Have life expectancy of ≥ 4 months.

          -  Have Child-Pugh Class A or B liver disease without encephalopathy or/and ascites.

        Exclusion Criteria:

          -  Have serious medical illnesses including, but not limited to, congestive heart
             failure, myocardial infarction or cerebral vascular accident within the last six
             months, or life threatening cardiac arrhythmias.

          -  Is scheduled for liver transplantation.

          -  Have previously received any treatment for HCC (except for study subjects being
             considered for completion of treatment or re-treatment).

          -  Have previously received any doxorubicin (study subjects being considered for
             completion of treatment or re-treatment may have received ThermoDox previously).

          -  Have extrahepatic metastasis.

          -  Are pregnant or breast-feeding. In women of childbearing potential, a negative
             pregnancy test (serum) is required prior to study treatment.

          -  Women of childbearing potential who are not practicing an acceptable form of birth
             control (i.e. diaphragm, cervical cap, condom, surgical sterility or birth control
             pills. Women whose partner has undergone a vasectomy must use a second form of birth
             control).

          -  Have any known allergic reactions to any of the drugs or liposomal components or
             intravenous imaging agents to be used in this study.

          -  Have portal or hepatic vein tumor invasion/thrombosis.

          -  Have INR &gt; 1.5 times the institution's upper normal limit (UNL), except in subjects
             who are therapeutically anticoagulated for medical conditions unrelated to HCC such as
             atrial fibrillation. Subjects may be re-screened after condition is treated or
             anticoagulant is withheld.

          -  Have platelet count &lt; 75,000/mm3, absolute neutrophil count &lt; 1500/mm3, or Hgb &lt; 10.0
             g/dL (unless the hemoglobin value has been stable, the subject is cardiovascularly
             stable, asymptomatic and judged able to withstand the RFA procedure).

          -  Have serum creatinine ≥ 2.5 mg/dL or calculated creatinine clearance (CrCl) ≤ 25.0
             mL/min.

          -  Have serum bilirubin &gt; 3.0 mg/dL.

          -  Have serum albumin &lt; 2.8 g/dL.

          -  Have body temperature &gt;1010F (38.30C) immediately prior to study treatment.

          -  Have contraindications to receiving doxorubicin HCl.

          -  Are being treated with other investigational agents.

          -  Use of an investigational drug within 30 days or 5 half-lives, whichever is longer,
             preceding the first dose of study medication (study subjects being considered for
             completion of treatment or re-treatment may have received ThermoDox previously).

          -  Have other concurrent malignancy (subjects with treated squamous cell carcinoma of the
             skin or basal cell carcinoma of the skin may be included), evidence of extrahepatic
             cancer from their primary malignancy, or ongoing, medically significant active
             infection.

          -  Documented HIV positive.

          -  NYHA class III or IV functional classification for heart failure.

          -  Evidence of hemachromatosis.

          -  Have history of contrast-induced nephropathy.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ronnie T Poon, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Queen Mary Hospital, University of Hong Kong</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Riccardo Lencioni, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>University of Pisa</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90095</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville, Florida</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Louisville</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mount Sinai School of Medicine</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Temple University Hospital</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19140</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Geisinger Health System</name>
      <address>
        <city>Wilkes Barre</city>
        <state>Pennsylvania</state>
        <zip>18711</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Texas Health Science Center</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vancouver General Hospital</name>
      <address>
        <city>Vancouver</city>
        <state>British Columbia</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto General Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 2L4</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The 1st Affiliated Hospital, Fujian Medical University</name>
      <address>
        <city>Fuzhou</city>
        <state>Fujian</state>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital</name>
      <address>
        <city>Wuhan</city>
        <state>Hubei</state>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Nanjing Drum Tower Hospital, The Affilitated Hospital of Nanjing University Medical School</name>
      <address>
        <city>Nanjing</city>
        <state>Jiangsu</state>
        <zip>210008</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Suzhou University</name>
      <address>
        <city>Suzhou</city>
        <state>Jiangsu</state>
        <zip>215006</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Hospital of Jilin University</name>
      <address>
        <city>Changchun</city>
        <state>Jilin</state>
        <zip>130021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin Cancer Hospital</name>
      <address>
        <city>Tianjin</city>
        <state>Tianjin</state>
        <zip>300060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Zhejiang University</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310013</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Institute and Hospital, Chinese Academy of Medical Sciences</name>
      <address>
        <city>Beijing</city>
        <zip>100021</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing Cancer Hospital, Peking University School of Oncology</name>
      <address>
        <city>Beijing</city>
        <zip>100036</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing You An Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Beijing You An Hospital，Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100069</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Southwest Hospital, The First Affiliated Hospital of the Third Military Medical University</name>
      <address>
        <city>Chongqing</city>
        <zip>400038</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sun Yat-Sen University Cancer Center</name>
      <address>
        <city>Guangzhou</city>
        <zip>510060</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Center of Nanfang Hospital, Southern Medical University</name>
      <address>
        <city>Guangzhou</city>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai Changhai Hospital, Second Military Medical University</name>
      <address>
        <city>Shanghai</city>
        <zip>200433</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tianjin No. 3 Central Hospital</name>
      <address>
        <city>Tianjin</city>
        <zip>300170</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera di Padova</name>
      <address>
        <city>Padova</city>
        <state>Veneto</state>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna Policlinico S.Orsola Malpighi</name>
      <address>
        <city>Bologna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ospedale Classificato San Giuseppe, Milano</name>
      <address>
        <city>Milano</city>
        <zip>20123</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20052</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale per lo Studio e la Cura dei Tumori &quot;Fondazione Pascale&quot; di Napoli</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Univeristaria Pisana</name>
      <address>
        <city>Pisa</city>
        <zip>56124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto dei Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>00144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Sanitaria Ospedaliera Ordine Mauriziano di Torino Presidio Ospedaliero &quot;Umberto I&quot;</name>
      <address>
        <city>Torino</city>
        <zip>10128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chiba University Hospital</name>
      <address>
        <city>Chiba</city>
        <zip>260-8677</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Iwate Medical University Hospital</name>
      <address>
        <city>Iwate</city>
        <zip>020-8505</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yamanashi Prefectural Central Hospital</name>
      <address>
        <city>Koufu City</city>
        <zip>400-8506</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mie University Hospital</name>
      <address>
        <city>Mie</city>
        <zip>514-8507</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saiseikai Niigata Daini Hospital</name>
      <address>
        <city>Niigata City</city>
        <zip>950-1104</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Okayama University Hospital</name>
      <address>
        <city>Okayama City</city>
        <zip>700-8558</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoundo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>101-0062</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>113-8655</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Japanese Red Cross Medical Center</name>
      <address>
        <city>Tokyo</city>
        <zip>150-8935</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>JR Tokyo General Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>151-8528</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kanto Central Hospital</name>
      <address>
        <city>Tokyo</city>
        <zip>158-8531</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wakayama Medical University</name>
      <address>
        <city>Wakayama</city>
        <zip>641-8510</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yokohama City University Medical Center</name>
      <address>
        <city>Yokohama City</city>
        <zip>232-0024</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Soonchunhyang University Bucheon Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Bucheon-si</state>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Gangnam-gu</state>
        <zip>135-710</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Inje University Ilsan Paik Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <state>Goyang-si</state>
        <zip>411-706</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Gyeongsangbuk-do</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Jongno-gu</state>
        <zip>110-744</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyungpook National University Hospital</name>
      <address>
        <city>Daegu</city>
        <state>Jung-gu</state>
        <zip>700-721</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Kangnam St.Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <state>Seocho-gu</state>
        <zip>137-701</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pusan National University Hospital</name>
      <address>
        <city>Busan</city>
        <zip>602-739</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyunggido</city>
        <zip>464-707</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Yonsei University Severance Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>120-752</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Korea University Medical Center Anam Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>136-705</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Medical City</name>
      <address>
        <city>Pasig City, Metro Manila</city>
        <zip>1605</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St. Luke's Medical Center</name>
      <address>
        <city>Quezon City</city>
        <zip>1112</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cardinal Santos Medical Center</name>
      <address>
        <city>San Juan City</city>
        <zip>1053</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chinese General Hospital and Medical Center</name>
      <address>
        <city>Sta Cruz, Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang-Gung Memorial Hospital - Chiayi Branch</name>
      <address>
        <city>Putzu City</city>
        <state>Chiayi</state>
        <zip>613</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Kao Shiung</name>
      <address>
        <city>KaoShiung</city>
        <state>Kaohsiung County</state>
        <zip>833</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Linkou</name>
      <address>
        <city>Linkou</city>
        <state>Taoyuan</state>
        <zip>333</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chang Gung Memorial Hospital - Keelung</name>
      <address>
        <city>Keelung</city>
        <zip>204</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>China Medical University Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>404</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taichung Veterans General Hospital</name>
      <address>
        <city>Taichung</city>
        <zip>407</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>100</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Taipei Veterans General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>112</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tri-Service General Hospital</name>
      <address>
        <city>Taipei</city>
        <zip>114</zip>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Songklanagarind Hospital</name>
      <address>
        <city>Hat Yai</city>
        <state>Songkla</state>
        <zip>90110</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>King Chulalongkorn Memorial Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10330</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Siriraj Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thammasat University Hospital</name>
      <address>
        <city>Pathumthani</city>
        <zip>12120</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>China</country>
    <country>Hong Kong</country>
    <country>Italy</country>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Taiwan</country>
    <country>Thailand</country>
    <country>United States</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 6, 2008</study_first_submitted>
  <study_first_submitted_qc>February 15, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 18, 2008</study_first_posted>
  <results_first_submitted>February 3, 2017</results_first_submitted>
  <results_first_submitted_qc>February 3, 2017</results_first_submitted_qc>
  <results_first_posted type="Actual">March 24, 2017</results_first_posted>
  <last_update_submitted>March 24, 2017</last_update_submitted>
  <last_update_submitted_qc>March 24, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">April 25, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>hepatocellular carcinoma</keyword>
  <keyword>liver cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Hepatocellular</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Liposomal doxorubicin</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>ThermoDox + RFA</title>
          <description>ThermoDox should be administered at 50 mg/m2. The infusion should start approximately 15 minutes before radiofrequency ablation begins and continue for approximately 30 minutes.
ThermoDox: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
        </group>
        <group group_id="P2">
          <title>Sham + RFA</title>
          <description>Sham infusion should start approximately 15 minutes before radiofrequency ablation begins and continue for approximately 30 minutes.
5% Dextrose Solution: Single 30 minute intravenous infusion</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="354"/>
                <participants group_id="P2" count="347"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="244"/>
                <participants group_id="P2" count="245"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="110"/>
                <participants group_id="P2" count="102"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>ThermoDox + RFA</title>
          <description>ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
ThermoDox: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
        </group>
        <group group_id="B2">
          <title>Sham + RFA</title>
          <description>Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
5% Dextrose Solution: Single 30 minute intravenous infusion</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="354"/>
            <count group_id="B2" value="347"/>
            <count group_id="B3" value="701"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;40</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>40-&lt;45</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>45-&lt;50</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="25"/>
                    <measurement group_id="B3" value="43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>50-&lt;55</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="86"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>55-&lt;60</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="57"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="107"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>60-&lt;65</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="65"/>
                    <measurement group_id="B2" value="64"/>
                    <measurement group_id="B3" value="129"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>65-&lt;70</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="44"/>
                    <measurement group_id="B2" value="45"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>70-&lt;75</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="42"/>
                    <measurement group_id="B3" value="93"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>75-&lt;80</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="33"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="67"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>80-&lt;85</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="32"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>85+</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Missing</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="87"/>
                    <measurement group_id="B2" value="84"/>
                    <measurement group_id="B3" value="171"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="267"/>
                    <measurement group_id="B2" value="263"/>
                    <measurement group_id="B3" value="530"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="42"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="68"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="19"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korean</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="83"/>
                    <measurement group_id="B2" value="91"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwanese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66"/>
                    <measurement group_id="B2" value="62"/>
                    <measurement group_id="B3" value="128"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Chinese</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="115"/>
                    <measurement group_id="B2" value="125"/>
                    <measurement group_id="B3" value="240"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Other</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="40"/>
                    <measurement group_id="B2" value="32"/>
                    <measurement group_id="B3" value="72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Philippines</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Taiwan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="68"/>
                    <measurement group_id="B2" value="63"/>
                    <measurement group_id="B3" value="131"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hong Kong</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Thailand</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Malaysia</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Japan</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Italy</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="32"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>China</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="104"/>
                    <measurement group_id="B2" value="104"/>
                    <measurement group_id="B3" value="208"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Korea, Republic of</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82"/>
                    <measurement group_id="B2" value="92"/>
                    <measurement group_id="B3" value="174"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause</title>
        <time_frame>3 years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>ThermoDox + RFA</title>
            <description>ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
ThermoDox: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
          </group>
          <group group_id="O2">
            <title>Sham + RFA</title>
            <description>Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
5% Dextrose Solution: Single 30 minute intravenous infusion</description>
          </group>
        </group_list>
        <measure>
          <title>Progression Free Survival Will be Measured From the Date of Randomization to the First Date on Which One of the Following Occurs. o Local Recurrence o Any New Distant Intrahepatic HCC Tumor o Any New Extrahepatic HCC Tumor o Death From Any Cause</title>
          <units>Time to Progression (months)</units>
          <param>Number</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="354"/>
                <count group_id="O2" value="347"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.97" lower_limit="11.47" upper_limit="19.26"/>
                    <measurement group_id="O2" value="13.87" lower_limit="11.14" upper_limit="16.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Overall Survival as Measured by Time From Randomization to Death or the End of the Study.</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Definite Worsening as Per Patient-Reported Outcomes</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Time to Local Recurrence.</title>
        <time_frame>3 years</time_frame>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Safety</title>
        <time_frame>3 years</time_frame>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>ThermoDox + RFA</title>
          <description>ThermoDox 50 mg/m2 start infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
ThermoDox: Thermally Sensitive Liposomal Doxorubicin 50 mg/m2 Single 30 minute intravenous infusion</description>
        </group>
        <group group_id="E2">
          <title>Sham + RFA</title>
          <description>Sham infusion over 30 minutes about 15 minutes before radiofrequency ablation begins.
5% Dextrose Solution: Single 30 minute intravenous infusion</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="118" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="37" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Febrile Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pancytopenia</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Anaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bone Marrow Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Myocardial Infarction</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cardiac Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cardio-respiratory arrest</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Myocardial Rupture</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Pericardial Effusion</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Upper Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="3" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Oesophageal Varices Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Ascites</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Diarrhoea</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Ileus</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Duodenal Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastric Ulcer Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastric Varices Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastritis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastrointestinal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastrooesophageal Reflux Disease</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Large Intestine Perforation</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Localised Intraabdominal Fluid Collection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Mesenteric Vein Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Peritoneal Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Portal Hypertensive Gastropathy</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Stress Ulcer</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Multi-organ Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Asthenia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hyperpyrexia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Oedema Peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Hepatobiliary disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Jaundice Cholestatic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bile Duct Stone</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hepatic Failure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hyperbilirubinaemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Jaundice</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Liver Disorder</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Liver Injury</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cellulitis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Liver Abscess</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neutropenic Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Peritonitis Bacterial</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Septic Shock</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Abdominal Infection</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Anal Abscess</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Bacteraemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Furuncle</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Gastritis Viral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Infected Cyst</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Salmonella Sepsis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wound Infection Staphylococcal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Hepatic Rupture</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Post Procedural Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Post Procedural Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Biloma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Fall</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hepatic Function Abnormal</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Puncture Site Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Skin laceration</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wound Haemorrhage</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="9" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Haemoglobin Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Diabetes Mellitus Inadequate Control</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypocalcaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hypoglycaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Hyponatraemia</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Metabolic Acidosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Musculoskeletal Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Tumour Thrombosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Hepatic encephalopthy</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Cerebral Ischaemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Convulsion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Depressed Level of Consciousness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Haemorrhagic Stroke</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Transient Ischaemic Attack</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Delirium Tremens</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Mood Altered</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Acute Prerenal Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Renal Failure Acute</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Urethral Stenosis</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Pleural Effusion</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Aspiration</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Chronic Obstructive Pulmonary Disease</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Haemothorax</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Respiratory Failure</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Surgical and medical procedures</title>
            <event_list>
              <event>
                <sub_title>Biliary Drainage</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Shock Haemorrhagic</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="327" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="301" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Neutropenia</sub_title>
                <counts group_id="E1" subjects_affected="87" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="6" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Leukopenia</sub_title>
                <counts group_id="E1" subjects_affected="73" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Thrombocytopenia</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Abdominal Pain</sub_title>
                <counts group_id="E1" subjects_affected="50" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" subjects_affected="53" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="43" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Abdominal Pain Upper</sub_title>
                <counts group_id="E1" subjects_affected="44" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="44" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Vomiting</sub_title>
                <counts group_id="E1" subjects_affected="35" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="28" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="21" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="15" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Abdominal Distension</sub_title>
                <counts group_id="E1" subjects_affected="15" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Pyrexia</sub_title>
                <counts group_id="E1" subjects_affected="56" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="98" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Fatigue</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="14" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="28" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Wound Complication</sub_title>
                <counts group_id="E1" subjects_affected="33" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="33" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Aspartate Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="70" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="70" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Alanine Aminotransferase Increased</sub_title>
                <counts group_id="E1" subjects_affected="61" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="62" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Blood Bilirubin Increased</sub_title>
                <counts group_id="E1" subjects_affected="29" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="39" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="48" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="12" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="38" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="9" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Platelet Count Decreased</sub_title>
                <counts group_id="E1" subjects_affected="20" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="20" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Blood Lactate Dehydrogenase Increased</sub_title>
                <counts group_id="E1" subjects_affected="19" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>Neutrophil Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="8" subjects_at_risk="334"/>
              </event>
              <event>
                <sub_title>White Blood Cell Count Increased</sub_title>
                <counts group_id="E1" subjects_affected="24" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Decreased Appetite</sub_title>
                <counts group_id="E1" subjects_affected="32" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Haematuria</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="23" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="26" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="49" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Alopecia</sub_title>
                <counts group_id="E1" subjects_affected="173" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="18" subjects_at_risk="343"/>
                <counts group_id="E2" subjects_affected="17" subjects_at_risk="334"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Nicholas Borys, M.D. Senior Vice President and Chief Medical Officer</name_or_title>
      <organization>Celsion Corporation</organization>
      <phone>609-896-9100</phone>
      <email>nborys@celsion.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

